Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 49 Women only

GenSci048 for moderate to severe endometriosis pain

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

Run by Changchun GeneScience Pharmaceutical Co., Ltd. · NCT06963177 · Data updated 2026-11-12

This study will test if GenSci048 reduces moderate to severe endometriosis pain in premenopausal women.

More Endometriosis-related Pain trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 49 Years
SexWomen only
Enrollment200 (estimated)
SponsorChangchun GeneScience Pharmaceutical Co., Ltd.
Industry-sponsored
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedMay 26, 2025
Main results expectedMay 15, 2028
Study endsJanuary 6, 2030
Registry record updatedAugust 12, 2025
Trial IDNCT06963177 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Premenopausal women aged 18–49 with a diagnosis of endometriosis within the past 10 years, regular menstrual cycles, and moderate to severe endometriosis-associated pain are the intended participants.

Probably not a fit

People who have had a hysterectomy or bilateral oophorectomy, cannot stop excluded medications, or do not meet the menstrual cycle criteria are unlikely to benefit from participating.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase IIa, placebo-controlled interventional trial gives premenopausal women with moderate to severe endometriosis-associated pain either GenSci048 or a matching placebo to compare pain relief and safety. Eligible participants are aged 18–49, have a diagnosis of endometriosis within the past 10 years, regular natural menstrual cycles, and must agree to use only permitted analgesics and non-hormonal contraception during the study. The trial will track changes in pain and record adverse events to determine whether GenSci048 provides meaningful symptom improvement. Specific dosing schedules and treatment duration are set by the sponsor and monitored throughout the study.

Why it matters

Potential benefit: If successful, GenSci048 could reduce endometriosis-related pain and improve daily functioning for affected women.

How similar studies have gone: Previous small studies of new targeted agents for endometriosis pain have shown mixed results, so the approach has some precedent but remains experimental.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Pre-menopausal female participants, between 18 and 49 years of age, inclusive, at the time of signing informed consent.
2. Participants must have a diagnosis of endometriosis within 10 years before screening.
3. Have moderate to severe endometrial related pain.
4. Have at least one regular, natural menstrual cycles (ranging from 21 to 35 days (inclusive)) before and during the screening period.
5. Agree to switch from her usual analgesic medication to only that which is permitted in the study from the screening period to the end of treatment and agree to stop using other treatments for endometriosis.
6. Agree to use non-hormonal contraception from the time of signing the informed consent until 4 weeks after the last dose of the study medication.

Exclusion Criteria:

1. Participants who have previously received hysterectomy and/or bilateral oophorectomy, or plan to undergo these procedures during the study period.
2. Participants who suffer from chronic pelvic and/or non-pelvic pain that is not caused by EM and require chronic analgesia or other chronic treatment, which is expected to affect the assessment of EAP.
3. Pelvic ultrasound screening indicating a need for surgery or suspicion of malignancy.
4. Participants with abnormal and undiagnosed vaginal and/or uterine bleeding within 3 months prior to screening.
5. Participants who plan to schedule elective surgery during the study; or those who have had a surgery within 4 months prior to screening and need ongoing pain management.
6. History of severe depression or post-traumatic stress disorder within the two years prior to screening, or history of any other severe mental disorder at any time.
7. History of drug or alcohol abuse within the six months prior to screening.
8. Participants who have participated in any other interventional clinical trial (including clinical trials of drugs and devices) within 1 month prior to screening.
9. Have used a prohibited long-acting anesthetic or immediate-release anesthetic for more than 2 consecutive weeks for the treatment of endometriosis associated pain in the 6 months prior to screening.
10. Participant is pregnant, breast feeding, or planning a pregnancy.

Where it's running

  • Peking University First Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.